Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution

Blood

Volumn 98, Issue 10, 2001, Pages 2935-2941

  Nösslinger, Thomas ^a   Reisner, Regina ^a   Koller, Elisabeth ^a   Grüner, Helga ^a   Tüchler, Heinz ^a   Nowotny, Hadwiga ^a   Pittermann, Elisabeth ^a   Pfeilstöcker, Michael ^a  

^a HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE CLASSIFICATION; DYSPLASIA; FEMALE; FRANCE; GRANULOPOIESIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEGAKARYOPOIESIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0035892129     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.10.2935     Document Type: Article

References (29)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
2. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol. 1995;91:612-617.
3. Verhoef GE, Pittaluga S, De Wolf-Peeters C, Boogaerts MA. FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol. 1995;71:3-11.
4. Michaux JL, Martiat P. Chronic myelomonocytic leukemia (CMML): a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma. 1993;9:35-41.
5. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative leukaemia group. Br J Haematol. 1994;87:746-754.
6. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res. 1998;22:871-878,
7. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma. 1995;17:79-85.
8. Germing U, Strupp C, Giagotinidis AS, Meckenstock G, Aul C. RAEB-T: a heterogenous entity [abstract]? Leuk Res. 1999;23:169.
9. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol. 1990;74:45-52.
10. Michels S, Chan W, Jakubowski D, Vogler R. Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype [abstract]. Lab Invest. 1990;62:67.
11. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia. 1996;10:20-26.
12. Matsuda A, Jinnai I, Yagasaki F, et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia. 1998;12:482-485.
13. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization of neoplastic diseases of the hematopoletic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
14. Schweizer D, Counterstained enhanced chromosome binding. Hum Genet. 1981;57:1-14,
15. Mitelman F, ed. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
16. Greenberg P, Cox C, LeBeau MM, et al, International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
17. Pfeilstöcker M, Reisner R, Nösslinger T, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol. 1999;106:455-463.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187,
20. Bennett J. The World Health Organization (WHO) classification of acute leukemias and the myelodysplastic syndromes. Int J Hematol. 2000;72:131-133.
21. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-992.
22. Sanz GF, Sanz MA, Villespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395-408.
23. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7:1315-1323.
24. Nösslinger T, Reisner R, Grüner H, et al. Dysplastic versus proliferative CMML-a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001;25:741-747.
25. Bernstein SH, Brunetto VL, Davey FR, et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996;14:2486-2494.
26. Jotterand M, Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma. 1996;23:253-266.
27. Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes: Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol. 2000;108:346-356.
28. Lewis S, Oscier D, Boultwood J, et al. Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion. Am J Hematol. 1995;49:194-200.
29. Mathew P, Tefferi A, Dewald GW, et al. The 5q syndrome: a single-institution study of 43 consecutive patients. Blood. 1993;81:1040-1045.